Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00272766 · ClinicalTrials.gov registry record · NA

Macugen for Histoplasmosis

A NA study, sponsored by Barnes Retina Institute.

Terminated
Registry status
NA
Development phase
24
Enrollment target

NCT00272766: Clinical Trial NA study, sponsored by Barnes Retina Institute.

NCT00272766 is a NA study that was terminated before completion, run by Barnes Retina Institute. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00272766, a NA study, was terminated before completion, sponsored by Barnes Retina Institute.

TERMINATED
Registry status
NA
Development phase
24 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the safety and effect on visual acuity of Macugen (pegaptanib sodium) in patients with subfoveal choroidal neovascularization (CNV) secondary to the ocular histoplasmosis syndrome (OHS).

Interventions

  • DRUG pegaptanib sodium

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2006-02
Est. Completion 2007-05
Phase NA
Barnes Retina Institute

6 total trials

Why NCT00272766 stopped before completion

NCT00272766 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which pegaptanib sodium is the first listed.

NCT00272766 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00272766 about?

NCT00272766 is a clinical study titled "Macugen for Histoplasmosis". The purpose of this study is to evaluate the safety and effect on visual acuity of Macugen (pegaptanib sodium) in patients with subfoveal choroidal neovascularization (CNV) secondary to the ocular histoplasmosis syndrome (OHS).

What is the current status of trial NCT00272766?

This trial is currently terminated. It is a NA study. The enrollment target is 24 participants. The study started on 2006-02. Estimated completion is 2007-05.

What interventions are being tested in trial NCT00272766?

The interventions under investigation include: pegaptanib sodium (DRUG).

Who is sponsoring clinical trial NCT00272766?

This trial is sponsored by Barnes Retina Institute, which has 6 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00272766's enrollment target sits among peer trials

24 1736th of 2000 higher than 246 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00272766, the US trial registry maintained by the National Library of Medicine. NCT00272766 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.